IS7435A - Indólamíðafleiður sem búa yfir tálmavirkni gegn glýkógenfosfórýlasa - Google Patents
Indólamíðafleiður sem búa yfir tálmavirkni gegn glýkógenfosfórýlasaInfo
- Publication number
- IS7435A IS7435A IS7435A IS7435A IS7435A IS 7435 A IS7435 A IS 7435A IS 7435 A IS7435 A IS 7435A IS 7435 A IS7435 A IS 7435A IS 7435 A IS7435 A IS 7435A
- Authority
- IS
- Iceland
- Prior art keywords
- indolamide
- inhibition
- glycogen phosphorylase
- derivatives possessing
- possessing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0205176.1A GB0205176D0 (en) | 2002-03-06 | 2002-03-06 | Chemical compounds |
| PCT/GB2003/000883 WO2003074484A1 (en) | 2002-03-06 | 2003-03-04 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7435A true IS7435A (is) | 2004-09-02 |
Family
ID=9932340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7435A IS7435A (is) | 2002-03-06 | 2004-09-02 | Indólamíðafleiður sem búa yfir tálmavirkni gegn glýkógenfosfórýlasa |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7138415B2 (is) |
| EP (1) | EP1483240A1 (is) |
| JP (1) | JP2005524667A (is) |
| KR (1) | KR20040097145A (is) |
| CN (1) | CN100374420C (is) |
| AR (1) | AR038889A1 (is) |
| AU (1) | AU2003216988A1 (is) |
| BR (1) | BR0308144A (is) |
| CA (1) | CA2477717A1 (is) |
| GB (1) | GB0205176D0 (is) |
| IL (1) | IL163823A0 (is) |
| IS (1) | IS7435A (is) |
| MX (1) | MXPA04008612A (is) |
| NO (1) | NO20044032L (is) |
| NZ (1) | NZ534683A (is) |
| PL (1) | PL373872A1 (is) |
| RU (1) | RU2004125182A (is) |
| TW (1) | TW200304817A (is) |
| WO (1) | WO2003074484A1 (is) |
| ZA (1) | ZA200406681B (is) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| MXPA05004968A (es) | 2002-11-07 | 2005-08-02 | Pfizer Prod Inc | N-(indol-z-carbonil)amidas como agentes anti-diabeticos. |
| GB0318464D0 (en) * | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0319690D0 (en) * | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| WO2005020985A1 (en) * | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity |
| US7214704B2 (en) | 2004-11-15 | 2007-05-08 | Bristol-Myers Squibb Company | 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006055435A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7226942B2 (en) | 2004-11-15 | 2007-06-05 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| EP1848693A1 (en) * | 2005-02-05 | 2007-10-31 | AstraZeneca AB | Indan-amide derivatives with glycogen phosphorylase inhibitory activity |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US10266526B2 (en) * | 2014-09-10 | 2019-04-23 | Epizyme, Inc. | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer |
| CN112442022B (zh) * | 2019-09-02 | 2022-05-20 | 承德医学院 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
| CN114403150B (zh) * | 2022-02-09 | 2022-11-04 | 中国农业大学 | 一种吲哚酰胺类化合物作为海藻糖-6-磷酸合成酶抑制剂的应用 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE200740C (is) | ||||
| US3706810A (en) | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
| DE3304019A1 (de) | 1983-02-07 | 1984-08-09 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 3-acyloxy-1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US4599198A (en) | 1985-08-02 | 1986-07-08 | Pfizer Inc. | Intermediates in polypeptide synthesis |
| US4668769A (en) | 1985-08-02 | 1987-05-26 | Hoover Dennis J | Oxa- and azahomocyclostatine polypeptides |
| US4720503A (en) | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| GB8522574D0 (en) | 1985-09-12 | 1985-10-16 | Lepetit Spa | Amides of teicoplanin compounds |
| FR2601368B1 (fr) | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| DE3629545A1 (de) | 1986-08-30 | 1988-03-10 | Bayer Ag | Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4791112A (en) | 1987-02-02 | 1988-12-13 | The Boc Group, Inc. | N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds |
| US4751231A (en) | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
| JPH02124756A (ja) | 1988-07-27 | 1990-05-14 | Suzuki Sangyo Kk | セメンティング組成物 |
| JPH04179949A (ja) | 1990-11-15 | 1992-06-26 | Fuji Photo Film Co Ltd | 新規な色素形成カプラーおよび該カプラーを用いたハロゲン化銀カラー写真感光材料 |
| WO1993025574A1 (en) | 1992-06-12 | 1993-12-23 | Pfizer Inc. | Inhibitors of angiotensin i chymase(s) including human heart chymase |
| ES2081747B1 (es) | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
| AU1890295A (en) | 1994-03-09 | 1995-09-25 | Novo Nordisk A/S | Piperidines and pyrrolidines |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| FR2723739B1 (fr) | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
| DE4445968A1 (de) | 1994-12-22 | 1996-06-27 | Bayer Ag | Verwendung von Sulfonylguanazinen |
| GB9504361D0 (en) * | 1995-03-04 | 1995-04-26 | Glaxo Spa | Heterocyclic compounds |
| US6107329A (en) * | 1995-06-06 | 2000-08-22 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| DE69522718T2 (de) | 1995-06-06 | 2002-02-07 | Pfizer | Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren |
| EP1134213B1 (en) | 1995-06-06 | 2005-11-02 | Pfizer Inc. | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides |
| CZ120398A3 (cs) * | 1995-09-08 | 1998-12-16 | Novo Nordisk A/S | Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty |
| WO1997031901A1 (en) | 1996-02-29 | 1997-09-04 | Mikael Bols | Hydroxyhexahydropyridazines |
| JP2000511173A (ja) | 1996-05-27 | 2000-08-29 | 藤沢薬品工業株式会社 | 一酸化窒素産生阻害剤としての新規なインドリルおよびベンゾフラニルカルボキサミド |
| US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| JP2001505585A (ja) | 1996-12-16 | 2001-04-24 | 藤沢薬品工業株式会社 | 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途 |
| AU6291098A (en) | 1997-03-07 | 1998-09-29 | Novo Nordisk A/S | Novel heterocyclic compounds |
| EP0983239A1 (en) | 1997-05-06 | 2000-03-08 | Novo Nordisk A/S | Novel heterocyclic compounds |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
| FR2786486B3 (fr) * | 1998-11-16 | 2000-12-08 | Sanofi Sa | Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates |
| ATE494388T1 (de) | 1999-01-13 | 2011-01-15 | Univ New York State Res Found | Neues verfahren zum erschaffen von proteinkinase- inhibitoren |
| AU2535700A (en) | 1999-02-12 | 2000-08-29 | Novo Nordisk A/S | Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation |
| JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
| US6043091A (en) | 1999-07-19 | 2000-03-28 | Isis Pharmaceuticals Inc. | Antisense modulation of liver glycogen phosphorylase expression |
| WO2001023347A1 (en) | 1999-09-29 | 2001-04-05 | Novo Nordisk A/S | Novel aromatic compounds |
| EP1088824B1 (en) | 1999-09-30 | 2004-01-07 | Pfizer Products Inc. | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
| SE9903998D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
| CA2389685C (fr) | 1999-11-05 | 2011-07-12 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R) | Nouveaux composes heterocycliques et leur application a titre de medicaments |
| DE60124861T2 (de) | 2000-01-21 | 2007-05-10 | Novartis Ag | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
| CO5271699A1 (es) | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| AR028253A1 (es) | 2000-03-16 | 2003-04-30 | Pfizer Prod Inc | Inhibidores de la glucogeno fosforilasa |
| PE20011184A1 (es) | 2000-03-16 | 2001-11-15 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
| EP1136071A3 (en) | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
| DK1145717T3 (da) | 2000-04-13 | 2004-08-02 | Pfizer Prod Inc | Synergistisk virkning af glyburid og milrinon |
| WO2001094300A1 (de) | 2000-06-09 | 2001-12-13 | Aventis Pharma Deutschland Gmbh | Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| US20020028826A1 (en) | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| IL144507A0 (en) | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| GB0021831D0 (en) | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| WO2002030894A2 (en) * | 2000-09-19 | 2002-04-18 | Taiho Pharmaceutical Co., Ltd. | Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins |
| AU2001288110A1 (en) | 2000-09-27 | 2002-04-08 | Takeda Chemical Industries Ltd. | Spiro compounds |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| JPWO2002036583A1 (ja) | 2000-11-01 | 2004-03-11 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗性医薬組成物 |
| AU2002256053A1 (en) | 2001-04-04 | 2002-10-21 | Genzyme Corporation | Novel bgp compounds for therapy and diagnosis and methods for using same |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| WO2002098348A2 (en) | 2001-06-01 | 2002-12-12 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| CA2465382A1 (en) | 2001-10-29 | 2003-05-08 | Japan Tobacco Inc. | Indole compound and medicinal use thereof |
| EP1451156A4 (en) | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOQUINOLINE COMPOUNDS |
| MXPA03000966A (es) | 2002-02-28 | 2003-09-04 | Pfizer Prod Inc | Agentes antidiabeticos. |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| JPWO2003091213A1 (ja) | 2002-04-25 | 2005-09-02 | アステラス製薬株式会社 | 新規なアミド誘導体又はその塩 |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| MXPA05004968A (es) | 2002-11-07 | 2005-08-02 | Pfizer Prod Inc | N-(indol-z-carbonil)amidas como agentes anti-diabeticos. |
| US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| JP2004196702A (ja) | 2002-12-18 | 2004-07-15 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド誘導体又はその塩 |
| US7501440B2 (en) | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
| EP1620427A1 (en) | 2003-04-17 | 2006-02-01 | Pfizer Products Inc. | Carboxamide derivatives as anti-diabetic agents |
| CA2521962A1 (en) | 2003-04-30 | 2004-11-11 | Pfizer Products Inc. | Anti-diabetic agents |
| WO2004113345A1 (ja) | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | 縮合ピロール化合物及びその医薬用途 |
| GB0318464D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0318463D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0319690D0 (en) | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| GB0319759D0 (en) | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| WO2005020985A1 (en) | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity |
| WO2005020986A1 (en) | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity |
| GB0320422D0 (en) | 2003-08-30 | 2003-10-01 | Astrazeneca Ab | Chemical compounds |
-
2002
- 2002-03-06 GB GBGB0205176.1A patent/GB0205176D0/en not_active Ceased
-
2003
- 2003-03-04 IL IL16382303A patent/IL163823A0/xx unknown
- 2003-03-04 CA CA002477717A patent/CA2477717A1/en not_active Abandoned
- 2003-03-04 EP EP03712310A patent/EP1483240A1/en not_active Withdrawn
- 2003-03-04 NZ NZ534683A patent/NZ534683A/en unknown
- 2003-03-04 KR KR10-2004-7013859A patent/KR20040097145A/ko not_active Application Discontinuation
- 2003-03-04 MX MXPA04008612A patent/MXPA04008612A/es active IP Right Grant
- 2003-03-04 JP JP2003572954A patent/JP2005524667A/ja not_active Withdrawn
- 2003-03-04 PL PL03373872A patent/PL373872A1/xx not_active Application Discontinuation
- 2003-03-04 CN CNB038053098A patent/CN100374420C/zh not_active Expired - Fee Related
- 2003-03-04 US US10/506,554 patent/US7138415B2/en not_active Expired - Fee Related
- 2003-03-04 WO PCT/GB2003/000883 patent/WO2003074484A1/en active Application Filing
- 2003-03-04 BR BR0308144-3A patent/BR0308144A/pt not_active IP Right Cessation
- 2003-03-04 AU AU2003216988A patent/AU2003216988A1/en not_active Abandoned
- 2003-03-04 RU RU2004125182/04A patent/RU2004125182A/ru not_active Application Discontinuation
- 2003-03-05 TW TW092104668A patent/TW200304817A/zh unknown
- 2003-03-06 AR ARP030100769A patent/AR038889A1/es unknown
-
2004
- 2004-08-23 ZA ZA200406681A patent/ZA200406681B/en unknown
- 2004-09-02 IS IS7435A patent/IS7435A/is unknown
- 2004-09-24 NO NO20044032A patent/NO20044032L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1483240A1 (en) | 2004-12-08 |
| NO20044032L (no) | 2004-10-05 |
| ZA200406681B (en) | 2005-09-22 |
| MXPA04008612A (es) | 2004-12-06 |
| WO2003074484A1 (en) | 2003-09-12 |
| KR20040097145A (ko) | 2004-11-17 |
| CA2477717A1 (en) | 2003-09-12 |
| IL163823A0 (en) | 2005-12-18 |
| JP2005524667A (ja) | 2005-08-18 |
| US7138415B2 (en) | 2006-11-21 |
| RU2004125182A (ru) | 2005-06-10 |
| PL373872A1 (en) | 2005-09-19 |
| AR038889A1 (es) | 2005-02-02 |
| CN1639120A (zh) | 2005-07-13 |
| GB0205176D0 (en) | 2002-04-17 |
| CN100374420C (zh) | 2008-03-12 |
| NZ534683A (en) | 2006-02-24 |
| TW200304817A (en) | 2003-10-16 |
| US20050107362A1 (en) | 2005-05-19 |
| BR0308144A (pt) | 2004-12-07 |
| AU2003216988A1 (en) | 2003-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7435A (is) | Indólamíðafleiður sem búa yfir tálmavirkni gegn glýkógenfosfórýlasa | |
| NO20043852L (no) | Heterocykliske amidderivater som inhibitorer av glykogen fosforylase | |
| IL184503A0 (en) | Pyrazole derivatives for the inhibition of cdk's and gsk's | |
| WO2004037176A3 (en) | Quinazolinones and derivatives thereof as factor xa inhibitors | |
| PT1711470E (pt) | Derivados de malonamida que bloqueiam a actividade de gama-secretase | |
| IS7749A (is) | Pýrimídínafleiður og notkun þeirra sem CB2 beina | |
| HU0101158D0 (en) | Use of glycogen phosphorylase inhibitors | |
| HK1096972A1 (en) | Inhibition of syk kinase expression | |
| AU2003285012A8 (en) | Compositions comprising zopiclone derivatives and methods of making and using the same | |
| HK1084043A1 (en) | Derivatives of aryl-quinazoline/aryl-2amino-phenylmethanone which promote the release of parathyroidhormone | |
| HK1070365A1 (en) | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | |
| NO20024386L (no) | Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer | |
| ZA200705614B (en) | Pyrazole derivatives for the inhibition of CDK's and GSK's | |
| HK1081185A1 (en) | Acyl derivatives of ziprasidone having neurolepticactivity | |
| PL372655A1 (en) | Compositions of pentafluoropropane | |
| IL148825A0 (en) | Derivatives of isoflavones | |
| AU2003212515A8 (en) | Indole-amide derivatives and their use as glycogen phosphorylase inhibitors | |
| AU2003261612A8 (en) | Derivatives of triptolide having high immunosuppressive effect and high water solubility, and uses thereof | |
| AU2003223702A1 (en) | Inhibition of platelet aggregation | |
| AU2003253701A1 (en) | 11-c-substituted derivatives of clarithromycin | |
| HUP0203929D0 (en) | New use of substituted alkyl-piridazinone derivatives | |
| FI20021940A0 (fi) | Avoimen rakentamisen tehokkaampi toteuttaminen | |
| FI20021941A0 (fi) | Avoimen rakentamisen tehokkaampi toteuttaminen | |
| TW556518U (en) | Structure of door for wardrobe | |
| PL360228A1 (en) | Application of carborates and metalcarborates and their derivatives |